ERAS

Erasca, Inc.

A clinical-stage biopharmaceutical company developing medicines for cancers driven by the RAS/MAPK pathway, one of the most frequently mutated signaling routes in human tumors. Founded in San Diego in 2018, its name blends "RAS" with "era," reflecting a mission to open a new era in treating RAS-driven cancers. The company is building a pipeline of experimental drugs aimed at this stubborn family of cancer-causing proteins.

CUSIP: 29479A108HealthcareUS1 holder

Ownership Activity Financials Filings

ERAS

ERAS

Other Events

Results of Operations and Financial Condition

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements

Other Events

Other Events

Submission of Matters to a Vote of Security Holders

Results of Operations and Financial Condition

Regulation FD Disclosure